Fabry Disease Market Analysis 2025 – Insights For Long-Term Investment & Planning

June 16, 2025 12:08 PM BST | By EIN Presswire
 Fabry Disease Market Analysis 2025 – Insights For Long-Term Investment & Planning
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

As per the data, the fabry disease market size has witnessed strong growth in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate CAGR of 8.2%. Factors such as increased awareness and diagnosis of rare diseases, improvement in specialized healthcare infrastructure, government incentives and orphan drug designations, as well as increased funding for rare disease research and initial launches of therapies are responsible for this growth.

What Is The Projected Future Growth Of The Fabry Disease Market Size?
Looking ahead, the fabry disease market size is poised for vigorous growth in the coming years. The market is anticipated to reach $3.10 billion in 2029, displaying a CAGR of 8.0%. Expansion of newborn screening programs, regulatory support for orphan and rare disease drugs, expansion of healthcare access, growth of telemedicine and remote care, and increasing demand for personalized medicine will dominant drivers in the forecast period. Noteworthy trends include adoption of enzyme replacement therapy, advancement in genetic testing, the use of AI and digital tools for early detection, the development of AI-powered diagnostic algorithms, and advancements in gene therapy.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What Are The Key Drivers Propelling The Growth Of The Fabry Disease Market?
A key growth driver propelling the fabry disease market's growth is the rising focus on personalized medicine. This approach uses information about a person's genes, environment, and lifestyle to tailor medical care and therapies specifically for better outcomes. It is anticipated to help improve treatment effectiveness and minimize side effects by tailoring therapies to individual patient needs. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients, significantly up from the six approvals in 2022.

What Key Player Strategies Are Driving The Fabry Disease Market?
Major companies in the fabry disease market include Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH. These industry players are focusing on developing innovative therapies, such as PEGylated enzyme replacement therapy ERT to enhance treatment efficacy, improve patient compliance, and reduce immunogenic responses associated with conventional ERTs.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

How Is The Fabry Disease Market Segmented?
Regarding market segmentation, the fabry disease market report covers the market by Type Type 1, Type 2, Other Types, Treatment Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments, Diagnosis Blood Test, Genetic Test, Parenteral Test, Other Diagnosis, Distribution Channel Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and End User Hospitals, Homecare, Specialty Clinics, Other End Users.

What Are The Regional Insights In The Fabry Disease Market?
With regards to geography, North America was the largest region in the fabry disease market in 2024. However, Asia-Pacific is anticipated to record the fastest growth in the forecast period.

Browse Through More Similar Reports By The Business Research Company:

Optogenetics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/optogenetics-global-market-report

Genetically Modified Animal Products Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/genetically-modified-animal-products-global-market-report

Genetic Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

About The Business Research Company
The Business Research Company, with its repository of over 15000+ reports across 27 industries and 60+ geographies, offers data-rich research and insights. Coupled with 1,500,000 datasets, an amalgamation of in-depth secondary research, and valuable insights from industry leaders, we provide information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next